
    
      PROTOCOL OUTLINE: This a dose escalation study to estimate the maximum tolerated dose of
      recombinant adenovirus encoded with the ornithine transcarbamylase gene.

      Patients receive a single dose of virus infused into the liver under fluoroscopic guidance.
      Groups of 3 patients receive successively higher doses of virus; each cohort is observed for
      safety for 3 weeks before entry of the next group.

      Patients are followed weekly for 1 month, then every 3 months until stable.
    
  